491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy

MLA

David G. Maloney, et al. “491 BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T-Cell Therapy.” Journal for ImmunoTherapy of Cancer, vol. 9, Nov. 2021, p. A522. EBSCOhost, https://doi.org/10.1136/jitc-2021-sitc2021.491.

APA

David G. Maloney, Armen Mardiros, Kirstin Liechty, Jason Perera, Diane M. Simeone, Ariane Lozac’hmeur, Karl Beutner, Michelle Fan-Port, Julian R. Molina, Scott Kopetz, William Y. Go, Eric Ng, J. Randolph Hecht, Sandip Pravin Patel, & Yi Lin. (2021). 491 BASECAMP-1: an observational study to identify relapsed solid tumor patients with human leukocyte antigen (HLA) loss of heterozygosity (LOH) and leukapheresis for future CAR T-cell therapy. Journal for ImmunoTherapy of Cancer, 9, A522. https://doi.org/10.1136/jitc-2021-sitc2021.491

Chicago

David G. Maloney, Armen Mardiros, Kirstin Liechty, Jason Perera, Diane M. Simeone, Ariane Lozac’hmeur, Karl Beutner, et al. 2021. “491 BASECAMP-1: An Observational Study to Identify Relapsed Solid Tumor Patients with Human Leukocyte Antigen (HLA) Loss of Heterozygosity (LOH) and Leukapheresis for Future CAR T-Cell Therapy.” Journal for ImmunoTherapy of Cancer 9 (November): A522. doi:10.1136/jitc-2021-sitc2021.491.